Ocrelizumab treatment in multiple sclerosis: A Danish population‐based cohort study
Luigi Pontieri(Rigshospitalet), Melinda Magyari(University of Copenhagen), Jonas M. Berg(Regionshospitalet Viborg), Michael Broksgaard Jensen(University of Southern Denmark), Viktoria Papp(Copenhagen University Hospital), Matthias Kant(Sygehus Sønderjylland), Morten Blinkenberg(Copenhagen University Hospital), Tine Iskov Kopp(Frederiksberg Hospital), Peter Vestergaard Rasmussen(Aarhus University Hospital), Stephan Bramow(Copenhagen University Hospital), Georgi Sirakov(Regional Hospital West Jutland), Jakob Schäfer(Aalborg University Hospital), Henrik Kahr Mathiesen(Gentofte Hospital), Hanna Joensen(Rigshospitalet), Finn Sellebjerg(Danish Multiple Sclerosis Center)
Cited by 29
Related Papers
Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility
|Science|2019|1.4k
Worldwide Incidence and Prevalence of Neuromyelitis Optica
|Neurology|2020|303
Clinical Relevance of Brain Volume Measures in Multiple Sclerosis
|CNS Drugs|2014|293
Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients With Relapsing-Remitting Multiple Sclerosis
|JAMA Neurology|2021|237
Apparent changes in the epidemiology and severity of multiple sclerosis
|Nature Reviews Neurology|2021|209